Back to results
US 2019/0194271 A1Published application
Fusion proteins for inhibiting angiogenesis
AssigneeAllgenesis Biotherapeutics Inc.
InventorsPei-Tzu WU, Jia-Hau SHIU, Madhu CHERUKURY, Tan NGUYEN, Kevin Zen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.
Claims21
A fusion protein comprising:
- an integrin binding peptide comprising disintegrin selected from a group consisting of an amino acid sequence of SEQ ID NO:
- 1 with at least one mutation on or adjacent to a RGD motif, an amino acid sequence having at least 85% sequence identity to SEQ ID NO:
- 1, and an amino acid sequence of SEQ ID NO:
- 2;
- other protein binding peptide targeting an angiogenic factor;
- and
- a Fc domain.
4 more elements
A fusion protein comprising:
- an integrin binding peptide comprising disintegrin targeting integrin αvβx or α5β1;
- other protein binding peptide targeting an angiogenic factor;
- and
- a Fc domain;
- wherein x is 1, 3, 5, 6 or 8.
2 more elements
Dependencies are inferred from the claim text.